AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tafluprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| prostaglandins | 4229 | 209860-87-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1 | 22 | |||
| kinase-selectivity-class | AXL,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 10, 2012 | FDA | OAK PHARMS INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 219.94 | 32.78 | 57 | 1167 | 33741 | 90593482 |
| Eye irritation | 158.02 | 32.78 | 44 | 1180 | 33934 | 90593289 |
| Eye pain | 150.96 | 32.78 | 45 | 1179 | 44123 | 90583100 |
| Eye pruritus | 114.12 | 32.78 | 33 | 1191 | 28994 | 90598229 |
| Intraocular pressure increased | 66.09 | 32.78 | 16 | 1208 | 7077 | 90620146 |
| Eye swelling | 58.95 | 32.78 | 20 | 1204 | 29366 | 90597857 |
| Vision blurred | 44.41 | 32.78 | 24 | 1200 | 110269 | 90516954 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 81.32 | 48.61 | 21 | 422 | 15942 | 42604950 |
| Eye irritation | 63.01 | 48.61 | 16 | 427 | 11302 | 42609590 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Ocular hyperaemia | 145.32 | 30.55 | 42 | 1362 | 39244 | 110548651 |
| Eye pain | 94.37 | 30.55 | 32 | 1372 | 50067 | 110537828 |
| Eye irritation | 77.52 | 30.55 | 25 | 1379 | 33427 | 110554468 |
| Eye pruritus | 61.92 | 30.55 | 21 | 1383 | 32754 | 110555141 |
| Intraocular pressure increased | 55.54 | 30.55 | 15 | 1389 | 10861 | 110577034 |
| Atrioventricular block second degree | 40.44 | 30.55 | 11 | 1393 | 8170 | 110579725 |
| Vision blurred | 36.93 | 30.55 | 22 | 1382 | 129000 | 110458895 |
| Pemphigoid | 34.75 | 30.55 | 12 | 1392 | 19695 | 110568200 |
| Cardiovascular insufficiency | 34.11 | 30.55 | 8 | 1396 | 3280 | 110584615 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | S01EE05 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues |
| FDA CS | M0017805 | Prostaglandins |
| FDA MoA | N0000000106 | Prostaglandin Receptor Agonists |
| FDA PE | N0000009526 | Increased Prostaglandin Activity |
| FDA EPC | N0000175454 | Prostaglandin Analog |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:66900 | prostaglandin receptor agonist |
Related Drugs by ATC class:
S01EE Prostaglandin analogues 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ocular hypertension | indication | 4210003 | DOID:9282 |
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0015% | ZIOPTAN | THEA PHARMA | N202514 | Feb. 10, 2012 | RX | SOLUTION/DROPS | OPHTHALMIC | 10864159 | May 28, 2029 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Prostaglandin F2-alpha receptor | GPCR | AGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4031331 | VUID |
| N0000184322 | NUI |
| D06274 | KEGG_DRUG |
| 4031331 | VANDF |
| C1451502 | UMLSCUI |
| CHEBI:66899 | CHEBI |
| CHEMBL1963683 | ChEMBL_ID |
| DB08819 | DRUGBANK_ID |
| C485333 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7451 | IUPHAR_LIGAND_ID |
| 8374 | INN_ID |
| 1O6WQ6T7G3 | UNII |
| 9868491 | PUBCHEM_CID |
| 1244607 | RXNORM |
| 187543 | MMSL |
| 26696 | MMSL |
| 013244 | NDDF |
| 699181001 | SNOMEDCT_US |
| 704470009 | SNOMEDCT_US |
| 1O6WQ6T7G3 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Tafluprost | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-6184 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | ANDA | 24 sections |
| ZIOPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-609 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | NDA | 25 sections |
| tafluprost | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-264 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | ANDA | 23 sections |
| Tafluprost | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-339 | SOLUTION/ DROPS | 0.02 mg | OPHTHALMIC | ANDA | 23 sections |
| Tafluprost Ophthalmic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-429 | SOLUTION/ DROPS | 0.00 mg | OPHTHALMIC | NDA authorized generic | 25 sections |
| ZIOPTAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82584-609 | SOLUTION/ DROPS | 0.02 mg | OPHTHALMIC | NDA | 26 sections |